Abstract
WH1fungin (WF), a lipopeptide surfactin, has been verified as an immunoadjuvant previously. In this study, mice were intranasally or parenterally immunized with WF plus Hepatitis B surface antigen (HBsAg), then the immune responses were detected. The results showed 50 µg WF plus 20 μg HBsAg for intranasal and 10 μg WF plus 1 µg HBsAg for parenteral immunization was efficient inducing strong immune response against HBsAg in mice. A high titer and longterm anti-HBsAg IgG was observed for more than 19 weeks in intranasal or parenteral immunizations, much higher than that induced by CpG or Alum adjuvant. The anti-HBsAg IgA was also induced in intestine and lung, indicating that mucosal as well as systemic immune response was elicited for intranasal immunization. The IgG isotype in serum revealed WF induced a Th2-bias immune response with a higher titer of anti-HBsAg IgG1 than IgG2a in mice. Moreover, WF also induced more Th1 cells producing interferon (IFN)-γ and stronger cytotoxic T lymphocytes response than controls for intramuscular administration. These data further confirmed that WF induced Th1- as well as Th2- type immune response toward HBsAg. Taken together, WF-adjuvanted HBsAg elicits more effective immune response than that adjuvanted by Alum or CpG, suggesting its potential for development of more efficient HBV vaccines in the future.
Keywords: Adjuvant, HBsAg, immune response, surfactin, vaccine.
Graphical Abstract
Protein & Peptide Letters
Title:A Surfactin Lipopeptide Adjuvanted Hepatitis B Vaccines Elicit Enhanced Humoral and Cellular Immune Responses in Mice
Volume: 21 Issue: 9
Author(s): Hui Pan, Xiuyun Zhao, Zhenqiu Gao and Gaofu Qi
Affiliation:
Keywords: Adjuvant, HBsAg, immune response, surfactin, vaccine.
Abstract: WH1fungin (WF), a lipopeptide surfactin, has been verified as an immunoadjuvant previously. In this study, mice were intranasally or parenterally immunized with WF plus Hepatitis B surface antigen (HBsAg), then the immune responses were detected. The results showed 50 µg WF plus 20 μg HBsAg for intranasal and 10 μg WF plus 1 µg HBsAg for parenteral immunization was efficient inducing strong immune response against HBsAg in mice. A high titer and longterm anti-HBsAg IgG was observed for more than 19 weeks in intranasal or parenteral immunizations, much higher than that induced by CpG or Alum adjuvant. The anti-HBsAg IgA was also induced in intestine and lung, indicating that mucosal as well as systemic immune response was elicited for intranasal immunization. The IgG isotype in serum revealed WF induced a Th2-bias immune response with a higher titer of anti-HBsAg IgG1 than IgG2a in mice. Moreover, WF also induced more Th1 cells producing interferon (IFN)-γ and stronger cytotoxic T lymphocytes response than controls for intramuscular administration. These data further confirmed that WF induced Th1- as well as Th2- type immune response toward HBsAg. Taken together, WF-adjuvanted HBsAg elicits more effective immune response than that adjuvanted by Alum or CpG, suggesting its potential for development of more efficient HBV vaccines in the future.
Export Options
About this article
Cite this article as:
Pan Hui, Zhao Xiuyun, Gao Zhenqiu and Qi Gaofu, A Surfactin Lipopeptide Adjuvanted Hepatitis B Vaccines Elicit Enhanced Humoral and Cellular Immune Responses in Mice, Protein & Peptide Letters 2014; 21 (9) . https://dx.doi.org/10.2174/0929866521666140418100743
DOI https://dx.doi.org/10.2174/0929866521666140418100743 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biomarkers for Early Detection of Colitis-associated Colorectal Cancer - Current Concepts, Future Trends
Current Drug Targets The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Topics in Medicinal Chemistry Meet Our Associate Editorial Board Member
Mini-Reviews in Medicinal Chemistry Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and Psoriatic Arthritis: A Systematic Review
Current Pharmaceutical Design EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Current Topics in Medicinal Chemistry Novel Serine Protease Dipeptidyl Peptidase IV Inhibitor: Alogliptin
Mini-Reviews in Medicinal Chemistry Current Therapeutic Concepts in Peripartum Cardiomyopathy
Current Pharmaceutical Design Toll-like Receptor 4 Mediates LPS-Induced Release of Nitric Oxide and Tumor Necrosis Factor-α by Embryonal Cardiomyocytes: Biological Significance and Clinical Implications in Human Pathology
Current Pharmaceutical Design Kruppel-Like Factors 4 and 5: Unity in Diversity
Current Genomics Meet Our Associate Editor
Current Molecular Medicine The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs
Current Drug Targets Moderate Wine Consumption in the Prevention of Metabolic Syndrome and its Related Medical Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets An Augmented Passive Immune Therapy to Treat Fulminant Bacterial Infections
Recent Patents on Anti-Infective Drug Discovery Renal Allograft Thrombosis
Current Pediatric Reviews Impact of IL-12 in Cancer
Current Cancer Drug Targets Immune Endocrinological Evaluation in Patients with Severe Vascular Acquired Brain Injuries: Therapeutical Approaches
Endocrine, Metabolic & Immune Disorders - Drug Targets Nephrotoxicity Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Drug Safety Cyclooxygenase-2 Pathway as a Potential Therapeutic Target in Diabetic Peripheral Neuropathy
Current Drug Targets Suppression of TLR Signaling by Targeting TIR domain-Containing Proteins
Current Protein & Peptide Science Fish Oil Fatty Acids as Cardiovascular Drugs
Current Vascular Pharmacology